Advertisement

Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY) announced the results of pre-clinical studies today using its RNA interference (RNAi) technology which it says could lead to the development of more effective vaccine therapies for cancer as well as infectious diseases.

Advertisement
Advertisement